IN THE SPECIFICATION

Please amend the first paragraph of page 1 as follows:

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of Application Serial 09/530,006 and now issued as U.S. Patent No. 6,680,305 which application was filed as Application No. PCT/US97/19964 on October 31, 1997; which application is a continuation-in-part of U.S. Application Serial No. 08/886,921 filed July 2, 1997 and now abandoned; which application is a continuation of U.S. Application Serial No. 08/780,974 filed January 9, 1997 and now abandoned; which application is a continuation of U.S. Application Serial No. 08/364,699 filed December 28, 1994 and now abandoned; which application is a continuation-in-part of U.S. Application Serial No. 08/253,384 filed June 3, 1994 and now issued as U.S. Patent No. 5,702,880; which application is a continuation-in-part of U.S. Application Serial No. 08/133,527 filed October 7, 1993 and now abandoned; which application is a continuation-in-part of U.S. Application Serial No. 08/071,533 filed June 4, 1993 and now issued as U.S. Patent No. 5,407,428; the disclosures of which are herein incorporated by reference.

Please add the following paragraph at page 9, beginning at line 9:

In one aspect of the invention, the solution contains two or more oncotic agents with differential clearance rates. The solutions of the present invention having two or more oncotic agents with differential clearance rates provide additional advantages in restoring blood oncotic pressure in a hypovolemic subject over an extended period of time, while encouraging the subject's own production of plasma proteins. Artificial oncotic agents with relatively slow clearance rates include high molecular weight Hetastarch (molecular weight 300,000-1,000,000) and dextran 70, measured to have intravascular persistence rates of 6 hours (Messmer (1989) Bodensee Symposium on Microcirculation (Hammersen & Messmer, eds.), Karger, N.Y., pg. 59). Artificial oncotic agents with relatively fast clearance rates include low and medium molecular weight Hetastarch (average molecular weight 40,000-200,000) and dextran 40, having intravascular persistence rates of 2-3 hours (Messmer (1989) supra).